Fidelity Investments
NAVB

Fidelity Investments’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Fidelity Investments’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,000
Closed -$260 – 5705
2023
Q1 		$260 Buy
+1,000
New +$292 ﹤0.01% 4838
2020
Q3 		– Sell
-26
Closed – – 4187
2020
Q2 		$0 Buy
+26
New +$50 ﹤0.01% 4456

Other funds holding NAVB

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PFO
Pathstone Family Office Englewood, New Jersey $13.1B AUM 21.02% 1-Year Est. Return

Fidelity Investments's NAVB Position: Q2 2023 in Review

Fidelity Investments sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2023, closing a stake of 1,000 shares — an estimated $260 sold.

Fidelity Investments first reported a position in NAVB in Q2 2020 and held it in 2 quarters. The position peaked at $260 in Q1 2023. 23 funds tracked by Wall St. Rank hold NAVB as of Q2 2023.

  • Fidelity Investments reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2023 after selling out during the quarter.
  • Fidelity Investments sold 1,000 Navidea Biopharmaceuticals Inc. shares in Q2 2023, an estimated $260.
  • Fidelity Investments first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2020 and held it in 2 quarters.
  • Fidelity Investments's Navidea Biopharmaceuticals Inc. position peaked at $260 in Q1 2023.
  • 23 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.